# EDGAR Filing Document

**Accession Number:** 0001691082
**File Stem:** 0001304340-25-000006
**Filing Date:** 2025-9
**Character Count:** 8750
**Document Hash:** 532b8965594e1208f78974d4ec19c9af
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001304340-25-000006.hdr.sgml**: 20250929

**ACCESSION NUMBER**: 0001304340-25-000006

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250910

**FILED AS OF DATE**: 20250929

**DATE AS OF CHANGE**: 20250929

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** PANOFF MARC L
- **CENTRAL INDEX KEY:** 0001304340

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42831
- **FILM NUMBER:** 251357860

**MAIL ADDRESS:**
- **STREET 1:** C/O RETROPHIN INC
- **STREET 2:** 777 THIRD AVENUE, 22ND FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LB PHARMACEUTICALS INC
- **CENTRAL INDEX KEY:** 0001691082
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 575 MADISON AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 917-450-6581

**MAIL ADDRESS:**
- **STREET 1:** 575 MADISON AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LB PHARMACEUTICALS INC.
- **DATE OF NAME CHANGE:** 20161129

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>PANOFF MARC L<br><sub>(Last) (First) (Middle)</sub><br>C/O LB PHARMACEUTICALS INC<br>ONE PENNSYLVANIA PLAZA, SUITE 1025<br><sub>(Street)</sub><br>NEW YORK, NY 10119<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-09-10 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Senior Vice President, Finance_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>LB PHARMACEUTICALS INC [ LBRX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Employee Stock Option (Right to Buy) | $64.15 | 2025-09-10 |  | D |  |  | 3944 | <sup>(1)</sup> | 2028-11-13 | Common Stock | 3944 | <sup>(2)</sup> | 0 | D |  |
| Employee Stock Option (Right to Buy) | $15 | 2025-09-10 |  | A |  | 3944 |  | <sup>(1)</sup> | 2028-11-13 | Common Stock | 3944 | <sup>(2)</sup> | 3944 | D |  |
| Employee Stock Option (Right to Buy) | $69.72 | 2025-09-10 |  | D |  |  | 896 | <sup>(1)</sup> | 2029-12-22 | Common Stock | 896 | <sup>(2)</sup> | 0 | D |  |
| Employee Stock Option (Right to Buy) | $15 | 2025-09-10 |  | A |  | 896 |  | <sup>(1)</sup> | 2029-12-22 | Common Stock | 896 | <sup>(2)</sup> | 896 | D |  |
| Employee Stock Option (Right to Buy) | $69.72 | 2025-09-10 |  | D |  |  | 1255 | <sup>(1)</sup> | 2030-08-30 | Common Stock | 1255 | <sup>(2)</sup> | 0 | D |  |
| Employee Stock Option (Right to Buy) | $15 | 2025-09-10 |  | A |  | 1255 |  | <sup>(1)</sup> | 2030-08-30 | Common Stock | 1255 | <sup>(2)</sup> | 1255 | D |  |
| Employee Stock Option (Right to Buy) | $41.84 | 2025-09-10 |  | D |  |  | 14343 | <sup>(3)</sup> | 2033-08-24 | Common Stock | 14343 | <sup>(2)</sup> | 0 | D |  |
| Employee Stock Option (Right to Buy) | $15 | 2025-09-10 |  | A |  | 14343 |  | <sup>(3)</sup> | 2033-08-24 | Common Stock | 14343 | <sup>(2)</sup> | 14343 | D |  |
| Employee Stock Option (Right to Buy) | $41.84 | 2025-09-10 |  | D |  |  | 7171 | <sup>(4)</sup> | 2034-06-26 | Common Stock | 7171 | <sup>(2)</sup> | 0 | D |  |
| Employee Stock Option (Right to Buy) | $15 | 2025-09-10 |  | A |  | 7171 |  | <sup>(4)</sup> | 2034-06-26 | Common Stock | 7171 | <sup>(2)</sup> | 7171 | D |  |
| Employee Stock Option (Right to Buy) | $15 | 2025-09-10 |  | A |  | 90525 |  | <sup>(5)</sup> | 2035-09-09 | Common Stock | 90525 | $0 | 90525 | D |  |

---

### Footnotes:

(1) Immediately exercisable.

(2) The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.

(3) One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

(4) One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

(5) One fourth (1/4) of the shares subject to the option award shall vest on September 10, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

**Signature:** /s/ Marc Panoff  
**Date:** 2025-09-12

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**